Drugs / YK-1169
last change Jun 2026 re-read 2 minutes ago

YK-1169

Developed for
bacterial pneumonia
Investigated by
Nanjing Yoko Biomedical Co., Ltd.

Trials 1 · a red edge is where a trial was stopped

20272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT07634198 Jun 2026 → Apr 2028 expected bacterial pneumonia Nanjing Yoko Biomedical Co., Ltd. Not yet recruiting No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05588531 Comparator Dec 2021 → Apr 2022 Nanjing Yoko Biomedical Co., Ltd. Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as YK-1169 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07634198
1

NCT05588531

Route Intravenous “single intravenous infusion for 2 hours” NCT05588531